secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001104659-25-104000
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia licenses Vectura's nebulizer device for treprostinil L606 in US PAH/PH-ILD
--------------------------------------------------------------------------------

- Upfront payment $2M; development milestones up to $12M; sales milestones up to $92.5M.
- Royalties in mid-single digits; Vectura to manufacture and supply the device.
- Exclusive US rights for treprostinil products treating hypertension and interstitial lung diseases (PAH, PH-ILD).
- Rights of first negotiation for additional territories and indications during term.
- Term until expiration of Royalty Term; termination for material breach, discontinuation, or patent challenge.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925104000/0001104659-25-104000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465925104000/tm2529678d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-104000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer